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Abstract
Background: Adverse transfusion reactions in the neonatal population are poorly understood and defined. The
incidence and pattern of adverse effects due to red blood cell (RBC) transfusion are not well known, and there has
been no systematic review of published adverse events. RBC transfusions continue to be linked to the development
of morbidities unique to neonates, including chronic lung disease, retinopathy of prematurity, intraventricular
haemorrhage and necrotising enterocolitis. Uncertainties about the exact nature of risks alongside benefits of RBC
transfusion may contribute to evidence of widespread variation in neonatal RBC transfusion practice.
Our review aims to describe clinical adverse effects attributed to small-volume (10–20 mL/kg) RBC transfusions and,
where possible, their incidence rates in the neonatal population through the systematic identification of all
relevant studies.
Methods: A comprehensive search of the following bibliographic databases will be performed: MEDLINE
(PubMed/OVID which includes the Cochrane Library) and EMBASE (OVID). The intervention of interest is small-volume
(10–20 mL/kg) RBC transfusions in the neonatal population.
We will undertake a narrative synthesis of the evidence. If clinical similarity and data quantity and quality permit, we
will also carry out meta-analyses on the listed outcomes.
Discussion: This systematic review will identify and synthesise the reported adverse effects and associations of RBC
transfusions in the neonatal population. We believe that this systematic review is timely and will make a valuable
contribution to highlight an existing research gap.
Trial Registration: PROSPERO, CRD42013005107
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013005107
Keywords: Transfusion/adverse effects, Neonates, Systematic review, Red blood cell transfusion, Transfusion reaction
Background
Anaemia of prematurity (AOP) is a multifactorial condi-
tion with diminished plasma erythropoietin (EPO) levels
in response to anaemia and hypoxia, reduced red cell life
span, phlebotomy losses for laboratory testing, limited
transplacental transfer of iron due to premature birth
and dependence on hepatic EPO production [1]. Small-
volume red blood cell (RBC) transfusions are often used
to manage AOP with over 90% of preterm neonates with
a birthweight at <1,000 g receiving at least one RBC
transfusion [2,3]. RBC transfusions are given with the as-
sumption that the transfusion will lead to an increase in
oxygen delivery to tissues, thereby providing a rapid and
effective intervention.
However, RBC transfusions are biological products, with
recognised risks. Adverse effects may be classified broadly
as those related to errors in the processing, storage and
administration or as actual medical complications. Inter-
pretation of the data from the UK Serious Hazards of
Transfusion (SHOT) National Haemovigilance Scheme of
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a population-based epidemiological study of transfused
patients has suggested that a disproportionate increased
number of adverse events occur in children compared to
adults, and more so in neonates [4]. A significant propor-
tion of these reports were related to transfusion errors, in-
cluding transfusion of an incorrect blood component.
While SHOT has received numerous reports related to
transfusion errors in the neonatal age group, there have
been relatively fewer adverse reactions to transfusion re-
ported. In the 2011 Annual SHOT report [5], there were
no reports of transfusion-related lung injury (TRALI) in
neonates. There were five paediatric reports classified as
transfusion-associated circulatory overload (TACO) that
included one neonate. It seems likely that there is under-
recognition and/or under-reporting of transfusion-related
adverse events in neonates [6,7] due to pre-existing critical
illness, in particular around the recognition of TRALI [8]
as many preterm neonates having intercurrent respira-
tory disease. This is compounded by the difficulties in de-
fining adverse transfusion events in a neonatal setting.
There are several recognised potential adverse associa-
tions related to RBC transfusions unique to neonates [9].
Associations between receipt of RBC transfusions and de-
velopment of necrotising enterocolitis [10], intraventricu-
lar haemorrhage [11,12] retinopathy of prematurity [13],
chronic lung disease [14] as well as mortality [15,16] have
all been described. The exact nature of these potential
risks, alongside benefits of RBC transfusions, has likely
contributed to widespread variation in neonatal RBC
transfusion practice [17]. To date, there has been no sys-
tematic collation of adverse effects due to, or associated
with, RBC transfusion in neonates nor assessment of the
degree to which biases operate to mitigate for or against
the strengths of associations with risks.
Our review aims to describe clinical adverse effects
attributed to small-volume (10–20 mL/kg) RBC transfu-
sions and, where possible, their incidence rates in the
neonatal population through the systematic identification
of all relevant studies. It is likely that our review will find
that reporting of adverse events related to neonatal trans-
fusion is variably described in the literature and there is a
need for standardisation of definitions in this area.
Methods/design
This review will be reported in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [18]. It has also
been registered in the PROSPERO international pro-
spective register of systematic reviews (registration num-
ber: CRD42013005107).
Study eligibility
We will include both randomised (including cluster-
randomised and quasi-randomised) and non-randomised
studies (including observational, cross-sectional, experi-
mental and retrospective), with the proviso that any ana-
lysis will be carried out separately for randomised and
non-randomised studies. Only studies examining the ef-
fects of RBC transfusion on neonates and have at least
one outcome deemed relevant to our review will be in-
cluded. Studies will not need to have a comparator
group to be included; however, only those with a com-
parator group will be used in any meta-analysis. Our re-
view will also focus its interpretation on those studies
with a comparator group.
We will exclude reviews, case series with less than five
neonatal participants, case reports, animal studies and
laboratory (in vitro) studies. We will exclude studies that
examine exchange transfusion, foetal (in utero) transfu-
sion, large-volume transfusions and transfusions used in
cardiac surgery and for extracorporeal membrane oxy-
genation (ECMO). These studies were excluded as we
have chosen to focus on the potential adverse effects of
small-volume RBC transfusions only.
Population
Neonates who received at least one RBC transfusion will
be considered. Infants are defined for the purposes of
this review as neonates less than 28 days of age and pre-
mature neonates (<37 weeks gestation) up to four weeks
post-term corrected age.
Interventions
The intervention of interest is small-volume (10–20
mL/kg) RBC transfusions.
Comparators
For studies with a comparator group, we will include
studies comparing
1. RBC transfusion with no RBC transfusion
2. Higher versus lower RBC transfusion threshold (or
comparisons among RBC transfusion thresholds)
3. Higher versus lower RBC transfusion volumes
4. RBC transfusion products (e.g. leukodepletion,
irradiation, age of RBC product, anticoagulant
preparation versus non-modified)
5. RBC transfusion with an alternative therapy
(e.g. erythropoietin-stimulating agents)
Outcomes
Depending on data availability, our outcomes will be
considered separately for ‘strong’ (e.g. immune-mediated
transfusion reactions) and ‘less certain’ (e.g. late-onset
sepsis, NEC, BPD, severe ROP, etc.) causal pathways
from transfusion to event.
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Primary outcomes
1. Mortality associated with receipt of RBC transfusion
i. Within 24–48 h of receipt of a RBC transfusion.
ii. Before discharge from initial hospitalisation.
2. Complications during hospital stay
Chronic lung disease (defined as requirement of
supplemental oxygen at 36 weeks gestation),
retinopathy of prematurity (grade 3 or above) [19],
necrotising enterocolitis (stage 2 or greater using
Bell's criteria) [20], intraventricular haemorrhage
(grade 3 or 4) [21], adverse neurodevelopmental
outcomes (at 18–24 months corrected age), cerebral
palsy diagnosed following physician assessment or
developmental delay (IQ or DQ > 2 standard
deviations below the mean on a validated assessment
tool of cognitive function), or blindness
(visual acuity).
Secondary outcomes
1. Adverse transfusion events
Immune-mediated transfusion reactions (acute
haemolytic transfusion reactions, febrile
non-haemolytic transfusion reactions and
transfusion-related acute lung injury) within 48 h of
receipt of RBC transfusion.
Acute non-immune-mediated transfusion
reactions (transfusion-related circulatory overload,
metabolic complications including hypocalcaemia,
hyperkalaemia, hyper/hypoglycaemia and
hypothermia) within 48 h of receipt of RBC
transfusion.
Alloimmunisation, transfusion-associated graft
versus host disease, post-transfusion purpura,
infectious adverse effects (transfusion-transmitted
infection, e.g. hepatitis B, hepatitis C, HIV, HTLV,
parasites), bacterial contamination/sepsis,
incorrect blood component transfused and/or
adverse events or reactions associated with
directed donation.
If data availability allows, we will examine adverse
transfusion events in the individual categories as
outlined above.
2. Longer-term outcomes
Long-term mortality, measured at 18–24 months,
associated with previous transfusion complications/
events in the neonatal period.
3. Adverse neurodevelopmental outcomes at
18–24 months, associated with previous transfusion
complications/events in the neonatal period.
Composite outcomes of relevance or additional
adverse events not previously identified will also
be included.
Search strategy
There will be no language restrictions, and we will at-
tempt to translate articles in languages other than Eng-
lish, depending on translational services available.
Literature published from 1990 onwards will be searched
and studies clearly completed prior to 1990 will be ex-
cluded. These studies will be excluded as since the
1990s, increasingly restrictive RBC transfusion practices
have been introduced and changes in RBC products
transfused (primarily leukoreduction) have occurred.
Literature and studies from 1990 onwards are more likely
to reflect current neonatal transfusion practices. We will
include studies available as full-text publications only
as it will be difficult to apply all selection criteria and ex-
tract data for abstract-only publications. A comprehen-
sive search of the following bibliographic databases will
be performed, including MEDLINE (PubMed/OVID),
EMBASE (OVID) and the CENTRAL database of the
Cochrane Library. We will also undertake hand searching
of reference lists and contact authors of relevant studies.
We will not review other grey literature. The search strat-
egy will include only terms relating to and describing the
participants and the intervention. We will use both free-
text terms and controlled vocabulary.
Selection of studies
Two reviewers will independently screen all electronic-
ally derived citations/abstracts of papers identified by
the review search strategy for relevance. At this stage,
screening will be based on title and abstract, and only
clearly irrelevant studies will be excluded. Full text will
be obtained for a selection of potentially relevant studies.
The two reviewers will then formally assess the full texts
for eligibility. If necessary, further information will be
sought from the authors where articles contain insuffi-
cient data to make a decision about eligibility. Potential
disagreements between the review authors will be re-
solved by consensus. If an agreement cannot be reached,
a third reviewer will adjudicate. Details of excluded stud-
ies will be recorded as well as reasons for exclusion. The
review authors will not be blinded to names of authors,
institutions, journals or the outcomes of the trials. If any
of the review group is an author on a paper identified in
the search, they will be excluded from making a decision
whether or not to include the study in the review, and
another member of the group will make the decision.
Data extraction
Two authors will conduct data extraction independently
using a data extraction form designed and piloted specif-
ically for this systematic review. The pilot process for
the data form will involve the two authors extracting
data from at least one of each of the included study
types for the review. The data extraction forms will then
Keir et al. Systematic Reviews 2014, 3:92 Page 3 of 5
http://www.systematicreviewsjournal.com/content/3/1/92
be reviewed by the two senior members of the author-
ship group and revised as required. Data extracted will
include information regarding study design, participants,
definitions of adverse effects and associations (out-
comes), RBC transfusion regimen and the control/com-
parison if applicable, neonatal adverse effects reported
and results relevant to the review, the risk of bias assess-
ment, including an assessment on confounding, rele-
vance and funding sources. Specific details regarding
adverse effects and associations, including grade or se-
verity, will also be collected including were they clearly
defined a priori and what was the period of follow-up of
study participants.
If an agreement cannot be reached over any aspects of
data extraction, a third reviewer will adjudicate.
Methodological quality assessment and risk of
bias assessment
Studies will not be excluded based on quality of research
methods. A formal risk of bias assessment will be per-
formed. For randomised controlled trials, the Cochrane
Collaboration's tool for assessing risk of bias will be used.
For non-randomised studies, a modified Newcastle-
Ottawa Scale (NOS) will be used to assess the quality of
non-randomised studies and it will also be used to assess
those without a comparator group. We are aware that
the Cochrane Collaboration is developing a new risk of
bias tool for non-randomised studies. If a working draft
is available in time, we will also consider relevant items
from this tool for inclusion into our risk of bias assess-
ment (modified NOS). We plan to undertake sensitivity
analysis by grading studies at low or high risk of bias
(qualitative assessment only). We will factor in all aspects
of risk of bias, for both qualitative and quantitative syn-
theses, when interpreting the evidence, and this will in-
clude formal risk of bias assessments, study design and
quantity of data. We will separately present findings in
tables for comparative and non-comparative studies. Al-
though conclusions will be drawn from both groups, the
focus of interpretation will be on studies with comparator
arms, and this will apply for any quantitative analysis.
Analysis plan
Qualitative synthesis
The main analysis will be descriptive. We will provide a
qualitative synthesis from the eligible studies, categorised
by the type of adverse effect for primary outcomes and
causal pathway for secondary outcomes. This section aims
to provide a summary of adverse effects attributed to the
receipt of RBC transfusion in the neonatal population.
Quantitative synthesis
If data allows a quantitative analysis of outcome data, we
will analyse separately randomised and non-randomised
studies. We are expecting that there will be heterogeneity
among included studies, and hence, random effects
models will be used to calculate separate pooled estimates
for each study type. If available and according to study
design, odds ratios (ORs), risk ratios (RRs), hazard ratios
(HRs) and incidence ratios (IRs) will be pooled separ-
ately. If the number of studies providing data is small,
and if the number of events is rather small, then it is ex-
pected that these relative measures will yield similar re-
sults. In this case, and in order to reduce heterogeneity
and provide more robust estimates, we will attempt to
transform ORs, RRs and HRs into a single metric [22],
and we will support this strategy with a sensitivity ana-
lysis by type of measure.
We will explore clinical heterogeneity concentrating
on the different RBC transfusion strategies and settings.
Statistical heterogeneity (where meta-analysis is feasible)
will be assessed by the I2 test, with values above 80%
classed as considerable heterogeneity. We will approach
pooling cautiously, and if I2 > 80%, we will not provide
pooled results, but instead we will provide information
either on a table or an un-pooled forest plot. If the data
permits, we will carry out subgroup analysis and sensi-
tivity analysis based on the different types of effect
measure (if they have been combined as mentioned earl-
ier). We will also carry out sensitivity analysis based on
the risk of bias assessment in terms of selection bias,
and any identified confounding factors.
Discussion
This systematic review will identify and synthesise the
reported adverse effects and associations of RBC transfu-
sions in the neonatal population.
The limited reporting of adverse effects in neonatal
transfusion trials, the quality of the studies identified as
well as the risk of bias inherent in studies in this area
are likely to be significant limitations to our review [9].
However, the identification and collation of all current
known adverse effects due to, or associated with, RBC
transfusion in neonates are key steps in improving the
reporting of these important events. The need for stan-
dardised neonatal definitions for all relevant adverse ef-
fects is also likely to be highlighted by this review, as
well as the need for consistent reporting.
By drawing together the current known adverse effects
and associations of RBC transfusion in neonates, we aim
to provide a clear overview of this area and clarify future
research areas. This protocol may also be used in the fu-
ture to examine the potential adverse effects of other
blood products and intravenous fluids used in the neo-
natal population. We believe that this systematic review
is timely and will make a valuable contribution through
highlighting existing research gaps.
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